KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. Ren S, Feng J, Ma S, Chen H, et al. Int J Cancer 2023;153:623-634.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ren S, Feng J, Ma S, Chen H, et al. KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. Int J Cancer 2023;153:623-634.
PMID: 37141294